XML 77 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note 12 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 62,840 $ 53,473 $ 178,843 $ 157,283
Gross profit 39,754 33,402 112,458 96,694
Operating expense 33,975 33,469 97,591 97,485
Operating income (loss) 5,779 (67) 14,867 (791)
Non-operating expense (income), net (7,996) 2,013 (9,367) 475
Operating Segments [Member]        
Gross profit 39,754 33,453 112,458 96,755
Operating expense 33,975 33,469 97,591 97,485
Operating income (loss) 5,779 (67) 14,867 (791)
Non-operating expense (income), net 7,996 (2,013) 9,367 (475)
(Loss) earnings before income taxes (2,217) 1,946 5,500 (316)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1],[2] 23,507 [3] 19,338 68,669 [4] 52,345
Gross profit [2] 16,461 13,951 47,191 38,018
Operating Segments [Member] | Clinical Genomics [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,667 12,546 35,570 41,464
Gross profit 6,948 6,449 19,344 20,904
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,237 9,430 36,112 28,526
Gross profit 7,539 5,841 22,665 17,783
Operating Segments [Member] | Calibration Solutions [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1] 14,429 12,159 38,492 34,948
Gross profit 8,806 7,212 23,258 20,050
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]        
Gross profit [5] $ 0 $ (51) $ 0 $ (61)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Includes post-acquisition GKE results during the three and six months ended September 30, 2024.
[3] Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.
[4] Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024.
[5] Unallocated corporate expenses are reported within corporate and other.